Last Price
0.93
Today's Change
-0.002 (0.21%)
Day's Change
0.91 - 0.94
Trading Volume
736,197
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Stephen R. Brady J.D., LLM Mr. Stephen R. Brady J.D., LLM
Full Time Employees: 17 17
IPO Date: 2012-11-12 2012-11-12
CIK: 0001544227 0001544227
ISIN: US87978U1088 US87978U1088
CUSIP: 87978U108 87978U108
Beta: -2.66 -2.66
Last Dividend: 0.00 0.00
Dcf Diff: -0.27 -0.27
Dcf: 1.20 1.20
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.